1. Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain.
- Author
-
Guzmán DC, Brizuela NO, Herrera MO, Olguín HJ, Peraza AV, García EH, Jiménez FT, and Mejía GB
- Subjects
- Animals, Brain metabolism, Dopamine metabolism, Hydrogen Peroxide pharmacology, Maltose pharmacology, Oxidation-Reduction drug effects, Rats, Wistar, Serotonin metabolism, Brain drug effects, Cytarabine pharmacology, Ferric Compounds pharmacology, Lipid Peroxidation drug effects, Maltose analogs & derivatives, Oxidative Stress drug effects
- Abstract
Background & Objective: The purpose of this study was to measure the effect on brain biomarkers after treatment with anticancer compounds - cytarabine (CT) and ferric carboxymaltose (FC) (Fe+3) in Wistar rats., Methods: The Wistar rats were treated as follows: group 1 (control), NaCl 0.9%; group 2, CT (25 mg/k), group 3, FC(Fe+3) (50 mg/k) and group 4, CT + FC(Fe+3). The animals were sacrificed and their brains were obtained and used to measure lipoperoxidation (TBARS), H2O2, Na+, K+ ATPase, glutathione (GSH), serotonin metabolite (5-HIAA) and dopamine. The results indicated an enhancement of lipid peroxidation in the cortex and striatum of groups treated with FC(Fe+3) and CT, while GSH decreased in the cortex of group treated with CT + FC(Fe+3). Dopamine decreased in the cortex of the rats that received CT, while in the striatum, 5HIAA increased in all groups., Results & Conclusion: These results suggest that the treatment with CT and FC(Fe+3) boosted oxidative stress and led to an alteration in momoamine concentrations in the brain., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF